(R)-3-mercapto-2-(4-methoxy-benzylamino)-propionic acid | 65776-11-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-3-mercapto-2-(4-methoxy-benzylamino)-propionic acid
• 英文别名: (R)-3-mercapto-2-(4-methoxybenzylamino)propanoic acid；(2R)-2-[(4-methoxyphenyl)methylamino]-3-sulfanylpropanoic acid
• CAS: 65776-11-6
• 化学式: C₁₁H₁₅NO₃S
• 分子量: 241.311
• InChiKey: DMNGECSBKZDBJE-JTQLQIEISA-N

物化性质

• 沸点：
  390.8±42.0 °C(Predicted)
• 密度：
  1.224±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  59.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-3-mercapto-2-(4-methoxy-benzylamino)-propionic acid 在 sodium hydroxide 、 乙酰氯 作用下， 以 乙醇 为溶剂， 反应 33.0h， 生成 3-(4-methoxybenzyl)-4-methoxycarbonyl-1,3-thiazolidine-2-thione
  参考文献：
  名称：

  Ghiaci; Tabrizi, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1998, vol. 37, # 1, p. 10 - 14

  摘要：

  DOI：
• 作为产物：
  描述：

  (2RS,4R)-2-(4-甲氧基苯基)-噻唑烷-4-羧酸 在 sodium hydroxide 、 sodium tetrahydroborate 、 水 、 potassium carbonate 、 溶剂黄146 作用下， 反应 1.0h， 以68%的产率得到(R)-3-mercapto-2-(4-methoxy-benzylamino)-propionic acid
  参考文献：
  名称：

  PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES

  摘要：

  本发明涉及用于制备3,4-二取代噻唑啉-2-酮的实用高产率合成过程，该过程不会损害化合物的绝对立体化学完整性。本发明还涉及3,4-二取代噻唑啉-2-酮的新化合物。本发明制备的化合物在合成和制造化合物（如拉特龙库林及/或其类似物）用于治疗与抑制肌动蛋白聚合有关的疾病或症状方面具有用处。

  公开号：

  US20070225504A1

文献信息

• Alpha-helical mimetics
  申请人：Lessene Guillaume Laurent

  公开号：US20080153802A1

  公开（公告）日：2008-06-26

  Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.

  公开了模拟α螺旋肽的苯甲酰脲衍生物，这些衍生物模拟BH3-仅蛋白，含有它们的组合物，它们与细胞靶向基团的结合，以及它们在调节细胞死亡中的用途。苯甲酰脲衍生物能够结合并中和促生存的Bcl-2蛋白。还描述了在治疗和/或预防与细胞死亡失调相关的疾病或症状中使用苯甲酰脲衍生物。
• Cytoskeletal active compounds, compositions and use
  申请人：Lampe W. John

  公开号：US20060217427A1

  公开（公告）日：2006-09-28

  The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.

  本发明涉及与天然拉曲林A或拉曲林B相关的合成细胞骨架活性化合物。本发明还涉及包含这些化合物和药用可接受载体的药物组合物。该发明还涉及一种预防或治疗与肌动蛋白聚合有关的疾病或症状的方法。在该发明的一个实施例中，该方法治疗增加的眼内压，如原发性开角型青光眼。该方法包括向受试者施用公式I或II的细胞骨架活性化合物的治疗有效量，其中所述量有效地影响细胞骨架，例如通过抑制肌动蛋白聚合。
• [EN] ALPHA-HELICAL MIMETICS<br/>[FR] MIMÉTIQUES D'HÉLICE ALPHA
  申请人：EARCH THE WALTER AND ELIZA HAL

  公开号：WO2006002474A1

  公开（公告）日：2006-01-12

  Benzoyl urea derivatives that are alpha helical peptide mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralising pro-survival Bcl-2 proteins. Use of the benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also disclosed.

  本文揭示了α螺旋肽类似物的苯甲酰脲衍生物，这些类似物模拟BH3-only蛋白质，包含它们的组合物，它们与细胞靶向基团的结合，以及它们在调控细胞死亡中的用途。苯甲酰脲衍生物能够结合并中和促生存的Bcl-2蛋白。还揭示了苯甲酰脲衍生物在治疗和/或预防与细胞死亡失调相关的疾病或症状中的用途。
• CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE
  申请人：Lampe W. John

  公开号：US20080076735A1

  公开（公告）日：2008-03-27

  The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.

  本发明涉及合成的细胞骨架活性化合物，其与天然拉曲林A或拉曲林B相关。本发明还涉及包含这种化合物和药学上可接受的载体的制药组合物。此外，本发明还涉及一种预防或治疗与肌动蛋白聚合有关的疾病或病症的方法。在本发明的一种实施例中，该方法治疗增加的眼内压，如原发性开角型青光眼。该方法包括向受试者给予公式I或II的细胞骨架活性化合物的治疗有效量，其中该量对细胞骨架产生影响，例如通过抑制肌动蛋白聚合。
• Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones
  申请人：Inspire Pharmaceuticals, Inc.

  公开号：US07947850B2

  公开（公告）日：2011-05-24

  The present invention is directed to practical high-yielding synthetic processes for preparing 3,4-disubstituted-thiazolidin-2-ones, which do not compromise the absolute stereochemical integrity of the compounds. The present invention is also directed to novel compounds of 3,4-disubstituted-thiazolidin-2-ones. The compounds prepared by the present invention are useful in the synthesis and manufacture of compounds (such as latrunculins and/or their analogs) for treating diseases or conditions associated with inhibiting actin polymerization.

  本发明涉及实用的高产率合成方法，用于制备3,4-二取代噻唑啉-2-酮，该方法不会损害化合物的绝对立体化学完整性。本发明还涉及3,4-二取代噻唑啉-2-酮的新化合物。通过本发明制备的化合物可用于合成和制造用于治疗与抑制肌动蛋白聚合相关的疾病或病症的化合物（例如拉曲林和/或其类似物）。